PCSK9 and familial hypercholesterolemia: To validate siAbasic and its potential therapeutic applications, the stability of transitional nucleation was examined for siRNA-6Ø against PCSK9 (PCS-B1, −3.6 kcal mol−1), developed for treating hypercholesterolemia (Figure 4A and Supplementary Table S8A) (28).